tissue analysis detect relevant somatic tumor alterations at similar rates in LUAC patients. Under-genotyping in tissue is common but can be mitigated by the use of cfDNA next generation sequencing assays.
Background: A growing number of targeted drug treatments in non-small cell lung cancer (NSCLC) have led to the need for molecular profiling beyond the standard of care (SOC) EGFR/ALK. Here we present actionable targets, impact on patient treatment, clinical trial opportunities and costs using the Illumina TruSight Tumor 15 panel (TST15) for NSCLC samples. Method: Tissue-based next generation sequencing using the TST15 was reflexively performed on all newly diagnosed cases of non-squamous NSCLC at the University Health Network (Toronto, Canada) from February 2017-February 2018. The panel identifies hot spot mutations in KRAS, EGFR, TP53, PIK3CA, BRAF, ERBB2, FOXL2, GNA11, GNAQ, KIT, NRAS, PDGFRA, RET, AKT1 and MET, but not fusions, copy number variations (CNV) nor MET exon 14 skipping mutations. Patient age, stage, pathologic subtype, and genotyping results were collected prospectively. Treatment changes as a result of TST15 and clinical trial opportunities (clinicaltrials. gov) were identified. Incremental testing costs were based on direct laboratory costs, but not personnel and administration costs. Background: Bain metastasis develops in approximately 50% of patients with non-small cell lung cancer (NSCLC), resulting in poor prognosis and low health-related quality of life. Immunological microenvironment and functions of ion channels have been indicated to play pertinent roles in epithelial-to-mesenchymal transition (EMT) and its reverse mesenchymal-to-epithelial transition (MET), crucial steps in distant metastasis, but their actual roles in brain metastasis of NSCLC remains unclear. The aim of this study is to investigate biologic profiles of brain metastasis of NSCLC. Method: Formalin-fixed paraffinembedded (FFPE) samples of brain metastasis and paired primary sites were collected from 3 patients with NSCLC undergoing surgical resection between Jan. 2012 and Dec. 2017. Total RNA was extracted from the archived FFPE, of which integrity was briefly checked by Nanodrop. Gene expression was detected by nCounter (NanoString Technologies, WA, USA) with PanCancer Immune Profilling Panel and custom-made KMU IonChannel Panel that covered selected 100 genes. Detected data was analyzed by nCounter Advanced Analysis (version 2.0.115). Factors with unadjusted P-value < 0.01 were regarded as candidates for further investigation. Result: Brain metastasis showed upregulations of MCOLN3 and YTHDF2 (unadjusted P-value¼ 0.0093 and 0.0063, respectively) compared to the primary site. Conversely, primary site showed upregulations of IFNAR1, TNFRSF4, CXCL11, CT45A1, MAP3K5, TAL1, LAG3 and MARCO. In LATE-BREAKING AB-STRACT, we will report following data: 1) Immunohistochemistry results of the candidate proteins in resected brain metastasis and primary sites of NSCLC from larger population. In situ hybridization is also planned. 2) Additional data of expression profiles of the candidate genes in sphere cell line from brain metastasis and primary site of NSCLC. Conclusion: Biologic profilings of brain metastasis from NSCLC may subsequently help to understand underlying mechanism and ultimately lead to novel targeted therapy. Further details will be added in LATE-BREAKING ABSTRACT. Keywords: Brain metastasis, ion channel, nCounter P2.03-06 Serum Syndechan-1 Levels in Patients with Nonsmall Cell Lung Cancer I. Tek, 1 O. Yetkin, 2 G. Yetkin, 3 M. Iraz 3 1 Medical Oncology, Medicana International Ankara Hastanesi, Ankara/TR, 2 Pulmonary Disease, Inonu University, Malatya/TR, 3 Microbiology, Inonu University, Malatya/TR Background: Cytokines as polypeptide or glycopeptide molecules are the essential mediators of immune response and the inflammatory reactions in addition to numerous biological reaction they are involved in. Syndecans have an important role in a variety of cellular functions including cell proliferation and migration, and cell-/cell and cell-/ matrix interactions. Syndechan-1 is a transmembrane heparan sulphate proteoglycans that is present on most cell types. In this study we aimed to evaluate the levels of syndecan-1, levels in non-small cell lung cancer (NSCLC), and to evaluate their relationship with tumor progression. Method: Sixtysix patients (F¼3, M¼63) with non-small cell lung cancer and 22 healthy (F¼3, M¼19) subject were enrolled this study. Patients with infections or other systemic disease were not included in the study. Serum levels of syndecan-1 was measured by ELISA system. Serum samples were obtained from each patient before the initiation of any type cancer treatment. They were centrifuged at 3000 rpm for 10min, and then stored at -70 C. Unpaired t-test was used to compare continuous variables between the patient group and control group and within the patient group according to TNM classification. Correlation analysis between cytokines and tumor stage was performed using the Pearson correlation coefficient. Sensitivity, specificity, positive predictive value and negative predictive values for syndecan-1 were determined using receiver operator characteristic analysis (ROC). These analyses were done to define clinically valid cutoff points to predict distant metastasis. A two-sided p values less than 0.05 was considered to be statistically significant. Result: Serum levels of syndecan-1 in patients with NSCLC were significantly higher than those of controls (p<0.001). In addition, mean levels of synde-can-1 in stage IV disease were significantly higher than non-metastatic NSCLC (p<0.001). In the patients with only one distant metastasis, levels of syndecan-1 were found to be lower than those of the patients with multiple distant metastases. Syndecan-1 has high sensitivity (78%), specificity (91%), positive (88%) and negative predictive (80%) values for prediction of metastasis. Conclusion: In conclusion, we found that syndecan-1 changes significantly in serum of patients with NSCLC. In our study, these changes correlated well with the stage of lung cancer. Syndecan-1 with a high sensitivity, specificity and positive predictive value may be used in predicting the presence and nature (single or multiple) of metastasis. The authors believe that the current findings will provide clinicians with new insights, allowing them to implement more individualized treatment strategies in patients with lung cancer. Keywords: nonsmall lung cancer, syndecan-1, metastasis
